Last reviewed · How we verify
pegylated filgrastim and filgrastim
Pegylated filgrastim and filgrastim stimulate the production of white blood cells, specifically neutrophils, to help the body fight infection.
Pegylated filgrastim and filgrastim stimulate the production of white blood cells, specifically neutrophils, to help the body fight infection. Used for Reduced febrile neutropenia in patients receiving myelosuppressive chemotherapy, Reduced infection risk in patients undergoing hematopoietic stem cell transplantation.
At a glance
| Generic name | pegylated filgrastim and filgrastim |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences |
| Drug class | G-CSF agonist |
| Target | G-CSF receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Filgrastim is a recombinant form of human granulocyte colony-stimulating factor (G-CSF), which is a naturally occurring protein that stimulates the bone marrow to produce more neutrophils. Pegylation of filgrastim increases its half-life and reduces its immunogenicity, allowing for more consistent and prolonged stimulation of neutrophil production.
Approved indications
- Reduced febrile neutropenia in patients receiving myelosuppressive chemotherapy
- Reduced infection risk in patients undergoing hematopoietic stem cell transplantation
Common side effects
- Bone pain
- Headache
- Nausea
- Injection site reaction
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: